Saving changes...

Done

Error

Cancer immunotherapy for dogs: Running behind humans

Cancer immunotherapy for dogs: Running behind humans

Cancer immunotherapy for dogs: Running behind humans

Veterinary Cancer Society
Veterinary Cancer Society
on behalf of Missouri Veterinary Medical Association

$FREE $ FREE $ FREE

$12.50 $ 12.50 $ 12.50

$ FREE $ FREE $ FREE
$ 12.50 $ 12.50 $ 12.50
Normal Price: FREE $12.50

Review:

Launch date: 07 Feb 2018

Expiry Date:

Last updated: 08 Feb 2018

Reference: 186914

Exam is embedded in the course
No preview available
No Exam Available

Latest User Comments

I would like to...

Course Availability

This course is only available to trainees days after purchase. It would need to be repurchased by the trainee if not completed in the allotted time period. This course is no longer available. You will need to repurchase if you wish to take the course again.

Description

Introduction: Compared to human patients, few immunotherapies have been developed for dogs. The intended goal of this presentation is to point to the issues that have hampered/are delaying th development of effective immuno-therapeutics for dogs, and what we can learn from studies in humans with respect to their feasibility and efficacy for canines.

Objectives

Objectives:
Introduction: Compared to human patients, few immunotherapies have been developed for dogs. The intended goal of this presentation is to point to the issues that have hampered/are delaying th development of effective immuno-therapeutics for dogs, and what we can learn from studies in humans with respect to their feasibility and efficacy for canines.
Veterinary Cancer Society

Author Information Play Video Bio

Veterinary Cancer Society
on behalf of Missouri Veterinary Medical Association

Dr. Hans Klingeman - Dr. Klingemann received his MD/PhD from the Universities of Würzburg and Marburg in Germany respectively. After a fellowship in Bone Marrow/ Stem Cell Transplantation at the Fred Hutchinson Cancer Research Center in Seattle, he joined the Stem Cell Transplant program at the University of British Columbia where he developed the NK-92 cell line for immunotherapy. Between 1997 and 2012 he directed transplant programs at Rush Medical Center in Chicago and Tufts Medical Center in Boston. In 2002 he co- founded the immunotherapy company ZelleRx which became NantKwest in 2015. Currently he is the company’s VP for R&D. Over the past 25 years Dr. Klingemann has conducted NCI funded research on how to engineer the patient’s immune system to fight cancer, resulting in over 200 peer-reviewed publications. He maintains an academic appointment at Tufts University Medical School.

Current Accreditations

This course has been certified by or provided by the following Certified Organization/s:

  • Missouri Veterinary Medical Association
  • 0.25 Hours -
    Exam Attempts: 3
    -
    Exam Pass Rate: 50

Faculty and Disclosures

Additional Contributors

Conflicts Declared

Conflicts of Interest declaration by Author:

null

User Reviews (0)

Go Back

Loading...


Saving changes...

Done

Error